Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NPA and SafetyCall

This article was originally published in The Tan Sheet

Executive Summary

The Natural Products Association partners with SafetyCall adverse event reporting call center to offer association members reduced rates on reporting services in preparation for changes in reporting requirements due to the implementation of the dietary supplement AER law Congress passed in 2006, NPA announces Nov. 7 (1"The Tan Sheet" Dec. 18, 2006, p. 6). SafetyCall and NPA also plan to conduct education events to help companies comply with the regulation and "ease the transition," NPA says. "We're happy to partner with the Natural Products Association and work with their members at a time when there's a rush to conform to the new reporting requirements," SafetyCall President, Regulatory and Scientific Affairs, Richard Kingston says. "We're confident that we can meet the increased demand and quickly respond to and document adverse event reports on behalf of participating association member companies," Kingston says...

You may also be interested in...

Adverse Event System Success Will Depend On Trained Reporters, Experts Say

Training potential reporters of adverse events may be crucial to the effectiveness of a mandatory adverse event reporting system, industry stakeholders say

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts